February 23, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to announce that its research arm, Cannevert Therapeutics Ltd, has been provided the Company with its latest research report outlining its progress with cannabis strains.
In Cannevert’s report, the strength and mix of research expertise and skillsets were highlighted along with the ‘lean and mean’ approach of being a discovery company. It also discussed the efficiency of identifying and quantifying all cannabinoids from various cannabis strains, the status of intellectual property protection of strains with therapeutic potential, and the plans for upcoming clinical trials in acute and chronic pain. There was also mention of some positive unexpected findings from animal studies, which will be further investigated and protected in due course. Pursuant to this study, initial meetings were made in the Netherlands with respect to the commencement of human trials.
Veritas CEO, Lui Franciosi stated, “We are pleased with the pace of Cannevert’s progress in identifying analgesic strains for clinical testing later this year. They have also made every effort to protect their findings with the help of Vancouver law firm, Oyen Wiggs Green & Mutala.”
About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect CTL’s IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.
About Cannevert Therapeutics Ltd.
CTL is a private company owned by a unique group of chemists, pharmacologists, and other medical professionals. With offices located on the campus of the University of British Columbia, CTL has obtained permission from Health Canada to conduct research on cannabis strains. CTL has entered a funding agreement with Veritas where, upon advancing $1.5 million to CTL, Veritas will earn an 80% ownership interest in CTL. Although Veritas has advanced $1,250,000 to CTL, no ownership interest will be earned by Veritas until the entire $1.5 million is received. CTL has also entered a licensing agreement with Veritas, licensing Veritas to market all products developed by CTL.
Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.
For more information, please visit our website: www.veritaspharmainc.com
On behalf of the Board of Directors; Veritas Pharma Inc.
“Dr. Lui Franciosi”
Dr. Lui Franciosi
Chief Executive Officer
Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com
Investor and Public Relations Contact
Veritas Pharma Inc.
Email: [email protected]
The CSE has not reviewed, nor approved or disapproved the content of this press release.